Page 45 - Read Online
P. 45

on second-line Fotemustine chemotherapy in recurrent   10.  Addeo R, Caraglia M, De Santi MS, Montella L,
               glioblastoma. J Neurooncol 2009;92:79-86.          Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V,
            6. Soffi etti R,  Trevisan E, Bertero L, Cassoni P, Morra I,   Genovese M, Cennamo G, Del Prete S.  A new schedule of
               Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G,   fotemustine in temozolomide-pretreated patients with relapsing
               Rudà R. Bevacizumab and fotemustine for recurrent   glioblastoma. J Neurooncol 2011;102:417-24.
               glioblastoma: a phase II study of AINO (Italian Association of   11.  Friedman HS, Prados MD,  Wen PY, Mikkelsen  T, Schiff D,
               Neuro-Oncology). J Neurooncol 2014;116:533-41.     Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R,
            7.   Wen PY, Macdonald DR, Reardon DA, Cloughesy  TF,   Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab
               Sorensen  AG, Galanis E, DeGroot J,  Wick M, Gilbert MR,   alone and in combination with irinotecan in recurrent
               Lassman  AB, Tsien  C,  Mikkelsen T, Wong  ET,     glioblastoma. J Clin Oncol 2009;27:4733-40.
               Chamberlain MC, Stupp R, Lamborn KR,  Vogelbaum MA,   12.  Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A,
               van der Bent MJ, Chang SM. Updated response assessment   Lou E, Sumrall  A,  Turner S, Sathornsumetee S, Rich JN,
               criteria for high-grade gliomas: response assessment in   Boulton S, Lipp ES, Friedman HS,  Vredenburgh JJ. Outcome
               neuro-oncology working group. J Clin Oncol 2010;28:1963-72.  after bevacizumab clinical trial therapy among recurrent grade III
            8.   Silvani  A, Lamperti E, Gaviani P, Eoli M, Fiumani  A,   malignant glioma patients. J Neurooncol 2012;107:213-21.
               Salmaggi  A, Falcone C, Filippini G, Botturi  A, Boiardi  A.
               Salvage chemotherapy with procarbazine and fotemustine   How to cite this article: Calvo OF, López MEP, Gómez JG. Complete
               combination in the treatment of temozolomide treated   response with fotemustine and bevacizumab after early progression
               recurrent glioblastoma patients. J Neurooncol 2008;87:143-51.  following radiotherapy and temozolomide treatment in patient with
            9.   Gaviani P, Salmaggi  A, Silvani  A. Combined chemotherapy   glioblastoma multiforme. J Cancer Metastasis Treat 2015;1:36-8.
               with temozolomide and fotemustine in recurrent glioblastoma   Received: 24-10-2014; Accepted: 23-02-2015.
               patients. J Neurooncol 2011;104:617-8.          Source of Support: Nil, Confl ict of Interest: None declared.


























































            38                                      Journal of Cancer Metastasis and Treatment  ¦  Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦
   40   41   42   43   44   45   46   47   48   49   50